skip to Main Content

Tapping the Expertise of Oncology CROs

Cancer drug development is perhaps the most arduous task with technically difficult, time-consuming, and expensive clinical trials being the lion’s share of that challenge.

This article examines the comparator arm drug access and reimbursement policies in Canada to help you make more informed trial expansion decisions. Despite the fact that Canada has some strong cards to play as a region for the expansion of both early and late phase oncology trials, you may have reservations simply because you are unfamiliar with the region’s drug availability and reimbursement landscape.

The increasing logistical complexity associated with conducting trials can be daunting, which is why more and more biopharmas are turning to niche contract research organizations with dedicated oncology expertise to help tap the best performing sites.

Be sure to Join the discussion in the Optimizing Oncology Clinical Research group on LinkedIn.

VIEW THE ARTICLE

Sign up to
Canadian Oncology
Trial News

  • This field is for validation purposes and should be left unchanged.
Back To Top
×Close search
Search